TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Wood, Lauren V ^a   Fojo, Antonio ^a   Roberson, Brenda D ^a   Hughes, Meghan S B ^a   Dahut, William ^a   Gulley, James L ^a   Madan, Ravi A ^a   Arlen, Philip M ^a   Sabatino, Marianna ^b   Stroncek, David F ^b   Castiello, Luciano ^b   Trepel, Jane B ^a   Lee, Min Jung ^a   Parnes, Howard L ^a   Steinberg, Seth M ^a   Terabe, Masaki ^a   Wilkerson, Julia ^a   Pastan, Ira ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Prostate cancer; PSA biochemical recurrence; TARP; therapeutic cancer vaccine

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; MONTANIDE; PROSTATE SPECIFIC ANTIGEN; TARP VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EXTERNAL BEAM RADIOTHERAPY; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; TUMOR GROWTH; VACCINATION;

EID: 84980384024     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1197459     Document Type: Article

References (43)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta:American Cancer Society; 2014. p.2, p.10; http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index
2. J.I.Epstein, W.C.Allsbrook, Jr, M.B.Amin, L.L.Egevad, I.G.Committee. 2005 International Society of Urological Pathology (ISUP) Consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29:1228-42; PMID:16096414; http://dx.doi.org/10.1097/01.pas.0000173646.99337.b1
3. A.Heidenreich, J.Bellmunt, M.Bolla, S.Joniau, M.Mason, V.Matveev, N.Mottet, H.P.Schmid, T.van der Kwast, T.Wiegel et al. EAU guidelines on prostate cancer. Part 1:screening, diagnosis, and treatment of clinically localized disease. Eur Urol 2011; 59:61-71; PMID:21056534; http://dx.doi.org/10.1016/j.eururo.2010.10.039
4. M.Essand, G.Vasmatzis, U.Brinkmann, P.Duray, B.Lee, I.Pastan. High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. Proc Natl Acad Sci U S A 1999; 96:9287-92; PMID:10430935; http://dx.doi.org/10.1073/pnas.96.16.9287
5. C.D.Wolfgang, M.Essand, J.J.Vincent, B.Lee, I.Pastan. TARP:a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci U S A 2000; 97:9437-42; PMID:10931945; http://dx.doi.org/10.1073/pnas.160270597
6. C.D.Wolfgang, M.Essand, B.Lee, I.Pastan. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Cancer Res 2001; 61:8122-6; PMID:11719440
7. F.R.Fritzsche, C.Stephan, J.Gerhardt, M.Lein, I.Hofmann, K.Jung, M.Dietel, G.Kristiansen. Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. Histol Histopathol 2010; 25:733-9; PMID:20376779; http://dx.doi.org/10.14670/HH-25.733
8. S.Varambally, J.Yu, B.Laxman, D.R.Rhodes, R.Mehra, S.A.Tomlins, R.B.Shah, U.Chandran, F.A.Monzon, M.J.Becich et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8:393-406; PMID:16286247; http://dx.doi.org/10.1016/j.ccr.2005.10.001
9. L.True, I.Coleman, S.Hawley, C.Y.Huang, D.Gifford, R.Coleman, T.M.Beer, E.Gelmann, M.Datta, E.Mostaghel et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006; 103:10991-6; PMID:16829574; http://dx.doi.org/10.1073/pnas.0603678103
10. C.J.Best, J.W.Gillespie, Y.Yi, G.V.Chandramouli, M.A.Perlmutter, Y.Gathright, H.S.Erickson, L.Georgevich, M.A.Tangrea, P.H.Duray et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11:6823-34; PMID:16203770; http://dx.doi.org/10.1158/1078-0432.CCR-05-0585
11. M.C.Nguyen, G.H.Tu, K.E.Koprivnikar, M.Gonzalez-Edick, K.U.Jooss, T.C.Harding. Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol, Immunother 2010; 59:1313-23; PMID:20499060; http://dx.doi.org/10.1007/s00262-010-0858-5
12. S.Oh, M.Terabe, C.D.Pendleton, A.Bhattacharyy, T.K.Bera, M.Epel, M.Epel, Y.Reiter, J.Phillips, W.M.Linehan et al. Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004; 64:2610-8; PMID:15059918; http://dx.doi.org/10.1158/0008-5472.CAN-03-2183
13. J.A.Berzofsky. Epitope selection and design of synthetic vaccines:molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann NY Acad Sci 1993; 690:256-64; PMID:7690214; http://dx.doi.org/10.1111/j.1749-6632.1993.tb44014.x
14. M.R.Parkhurst, M.L.Salgaller, S.Southwood, P.F.Robbins, A.Sette, S.A.Rosenberg, Y.Kawakami. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157:2539-48; PMID:8805655
15. J.D.Ahlers, T.Takeshita, C.D.Pendleton, J.A.Berzofsky. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 1997; 94:10856-61; PMID:9380724; http://dx.doi.org/10.1073/pnas.94.20.10856
16. P.Sarobe, C.D.Pendleton, T.Akatsuka, D.Lau, V.H.Engelhard, S.M.Feinstone, J.A.Berzofsky. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 1998; 102:1239-48; PMID:9739058; http://dx.doi.org/10.1172/JCI3714
17. D.A.Gross, S.Graff-Dubois, P.Opolon, S.Cornet, P.Alves, A.Bennaceur-Griscelli, O.Faure, P.Guillaume, H.Firat, S.Chouaib et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113:425-33; PMID:14755339; http://dx.doi.org/10.1172/JCI200419418
18. S.Tourdot, A.Scardino, E.Saloustrou, D.A.Gross, S.Pascolo, P.Cordopatis, F.A.Lemonnier, K.Kosmatopoulos. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1- associated peptides:implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000; 30:3411-21; PMID:11093159; http://dx.doi.org/10.1002/1521-4141(2000012)30:12%3c3411::AID-IMMU3411%3e3.0.CO;2-R
19. B.Carlsson, T.H.Totterman, M.Essand. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. The Prostate 2004; 61:161-70; PMID:15305339; http://dx.doi.org/10.1002/pros.20091
20. H.Kobayashi, T.Nagato, K.Oikawa, K.Sato, S.Kimura, N.Aoki, R.Omiya, M.Tateno, E.Celis. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 2005; 11:3869-78; PMID:15897588; http://dx.doi.org/10.1158/1078-0432.CCR-04-2238
21. P.M.Arlen, F.Bianco, W.L.Dahut, A.D'Amico, W.D.Figg, S.J.Freedland, J.L.Gulley, P.W.Kantoff, M.W.Kattan, A.Lee et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179:2181-5; discussion 5–6; PMID:18423743; http://dx.doi.org/10.1016/j.juro.2008.01.099
22. C.R.Pound, A.W.Partin, M.A.Eisenberger, D.W.Chan, J.D.Pearson, P.C.Walsh. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-7; PMID:10235151; http://dx.doi.org/10.1001/jama.281.17.1591
23. S.J.Freedland, E.B.Humphreys, L.A.Mangold, M.Eisenberger, F.J.Dorey, P.C.Walsh, A.W.Partin. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294:433-9; PMID:16046649; http://dx.doi.org/10.1001/jama.294.4.433
24. S.F.Slovin, A.S.Wilton, G.Heller, H.I.Scher. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005; 11:8669-73; PMID:16361552; http://dx.doi.org/10.1158/1078-0432.CCR-05-1668
25. A.K.Lee, L.B.Levy, R.Cheung, D.Kuban. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 2005; 63:456-62; PMID:15927415; http://dx.doi.org/10.1016/j.ijrobp.2005.03.008
26. S.J.Freedland, E.B.Humphreys, L.A.Mangold, M.Eisenberger, F.J.Dorey, P.C.Walsh, A.W.Partin. Death in patients with recurrent prostate cancer after radical prostatectomy:prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25:1765-71; PMID:17470867; http://dx.doi.org/10.1200/JCO.2006.08.0572
27. E.S.Antonarakis, M.L.Zahurak, J.Lin, D.Keizman, M.A.Carducci, M.A.Eisenberger. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents:combined analysis of 4 phase II trials. Cancer 2012; 118:1533-42; PMID:21960118; http://dx.doi.org/10.1002/cncr.26437
28. W.D.Stein, J.L.Gulley, J.Schlom, R.A.Madan, W.Dahut, W.D.Figg, Y.M.Ning, P.M.Arlen, D.Price, S.E.Bates et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials:the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17:907-17; PMID:21106727; http://dx.doi.org/10.1158/1078-0432.CCR-10-1762
29. M.R.Smith, J.Manola, D.S.Kaufman, W.K.Oh, G.J.Bubley, P.W.Kantoff. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24:2723-8; PMID:16782912; http://dx.doi.org/10.1200/JCO.2005.03.7804
30. T.M.Beer, G.T.Bernstein, J.M.Corman, L.M.Glode, S.J.Hall, W.L.Poll, P.F.Schellhammer, L.A.Jones, Y.Xu, J.W.Kylstra et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17:4558-67; PMID:21558406; http://dx.doi.org/10.1158/1078-0432.CCR-10-3223
31. C.Lonchay, P.van der Bruggen, T.Connerotte, T.Hanagiri, P.Coulie, D.Colau, S.Lucas, A.Van Pel, K.Thielemans, N.van Baren et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14631-8; PMID:15452345; http://dx.doi.org/10.1073/pnas.0405743101
32. C.Lurquin, B.Lethe, E.De Plaen, V.Corbiere, I.Theate, N.van Baren, P.G.Coulie, T.Boon. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201:249-57; PMID:15657294; http://dx.doi.org/10.1084/jem.20041378
33. B.A.Fox, D.J.Schendel, L.H.Butterfield, S.Aamdal, J.P.Allison, P.A.Ascierto, M.B.Atkins, J.Bartunkova, L.Bergmann, N.Berinstein et al. Defining the critical hurdles in cancer immunotherapy. J Translat Med 2011; 9:214; PMID:22168571; http://dx.doi.org/10.1186/1479-5876-9-214
34. B.Mlecnik, M.Tosolini, A.Kirilovsky, A.Berger, G.Bindea, T.Meatchi, P.Bruneval, Z.Trajanoski, W.H.Fridman, F.Pagès et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
35. J.Galon, F.Pages, F.M.Marincola, M.Thurin, G.Trinchieri, B.A.Fox, T.F.Gajewski, P.A.Ascierto. The immune score as a new possible approach for the classification of cancer. J Translat Med 2012; 10:1; PMID:22214470; http://dx.doi.org/10.1186/1479-5876-10-1
36. W.D.Stein, W.D.Figg, W.Dahut, A.D.Stein, M.B.Hoshen, D.Price, S.E.Bates, T.Fojo. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival:a novel strategy for evaluation of clinical trial data. Oncologist 2008; 13:1046-54; PMID:18838440; http://dx.doi.org/10.1634/theoncologist.2008-0075
37. R.A.Madan, J.L.Gulley, T.Fojo, W.L.Dahut. Therapeutic cancer vaccines in prostate cancer:the paradox of improved survival without changes in time to progression. Oncologist 2010; 15:969-75; PMID:20798195; http://dx.doi.org/10.1634/theoncologist.2010-0129
38. J.L.Gulley, R.A.Madan, W.D.Stein, J.Wilkerson, W.L.Dahut, C.R.Heery, J.Schlom, G.Wilding, R.S.DiPaola. Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. J Clin Oncol 2013; 31(suppl 6); abstr 57
39. J.L.Gulley, C.G.Drake. Immunotherapy for prostate cancer:recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011; 17:3884-91; PMID:21680544; http://dx.doi.org/10.1158/1078-0432.CCR-10-2656
40. M.J.Welters, G.G.Kenter, S.J.Piersma, A.P.Vloon, M.J.Lowik, D.M.Berends-van der Meer, J.W.Drijfhout, A.R.Valentijn, A.R.Wafelman, J.Oostendorp et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14:178-87; PMID:18172269; http://dx.doi.org/10.1158/1078-0432.CCR-07-1880
41. G.M.Higa, J.Abraham. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007; 7:1183-92; PMID:17892419; http://dx.doi.org/10.1586/14737140.7.9.1183
42. G.Liu, Y.H.Chen, J.Kolesar, W.Huang, R.Dipaola, M.Pins, M.Carducci, M.Stein, G.J.Bubley, G.Wilding. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 2013; 31:211-8; PMID:21784672; http://dx.doi.org/10.1016/j.urolonc.2011.01.002
43. O.E.Rahma, J.M.Hamilton, M.Wojtowicz, O.Dakheel, S.Bernstein, D.J.Liewehr, S.M.Steinberg, S.N.Khleif. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Translat Med 2014; 12:55; http://dx.doi.org/10.1186/1479-5876-12-55